Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
South Korea Stocks Tumble as AI-Fueled Rally Faces Profit-Taking Pressure 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Wall Street Slides as AI Stocks Tumble Following South Korea Tech Sell-Off 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
U.S.-Iran Diplomacy Helps Drive Gasoline Prices Down 15% From May Highs 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
